Stratistics MRC에 따르면 감마 부티로락톤 세계 시장은 2025년에 41억 달러, 예측 기간 동안 CAGR은 5.3%를 나타내고, 2032년에는 58억 8,000만 달러에 이를 전망입니다.
감마 부티로락톤(GBL)은 일반적으로 솔벤트 및 화학 중간체로 사용되는 무색의 흡습성 액체 유기 화합물입니다. GBL은 의약품, 고분자, 배터리 화학물질 생산에 중요한 역할을 합니다. 또한 N-메틸-2-피롤리돈(NMP)과 같은 다른 화합물의 전구체이기도 합니다.
의약품에 대한 수요 증가
GBL은 마취제와 진정제를 포함한 다양한 의약품의 합성에 있어서 전구체로서의 역할을 합니다. 제약 제조 분야에서 고순도 용매에 대한 수요가 증가함에 따라 시장 확장이 촉진되고 있습니다. 고급 의약 제제에 대한 규제 당국의 지원이 GBL 기반 용제의 채택을 뒷받침하고 있습니다.
변동하는 원료 가격
GBL의 생산은 전구체 화학물질에 의존하고 있으며, 그 비용은 지정학적 긴장이나 공급 체인의 혼란에 의해 변동합니다.
폴리머와 수지의 생산 증가
GBL은 폴리우레탄의 합성에 널리 사용되고 있으며, 자동차, 건축, 가구 산업에 필수적입니다. 특히 신흥국에서는 이러한 분야의 확대가 고성능 폴리머의 필요성을 높이고 있습니다. 게다가, 폴리머 기술의 진보는 GBL 기반 배합의 채택을 늘리고 있습니다. 수지 제조에서 GBL의 범용성은 시장의 잠재력을 높이고 있습니다. 산업계가 혁신적인 재료를 추구함에 따라 GBL 수요가 증가할 것으로 예측됩니다.
대체 용매와의 경쟁
특정 화학 용제에 대한 규제 제한으로 인해 산업계는 환경 친화적인 대체 용제를 찾고 있습니다. 일부 대체품은 유사한 성능 특성을 저비용으로 제공하며 GBL 시장 위치에 도전하고 있습니다. 또한 솔벤트 기술의 발전으로 보다 효율적인 대체 솔벤트 개발도 진행되고 있습니다. 지속가능한 솔벤트 솔루션에 투자하는 기업은 GBL 기반 제형에서 전환할 수 있습니다. 그 결과 대체 용매와의 경쟁이 시장 확대의 주요 위협이 되었습니다.
COVID-19의 영향
COVID-19의 유행은 감마 부티로락톤 시장에 다양한 영향을 미쳤습니다. 공급망의 혼란은 생산에 영향을 미쳤지만, 의약용 용매 수요는 급증했습니다. 락다운이나 규제에 의해 자동화된 제조 공정에의 의존이 높아져, GBL의 채택에 플러스가 되었습니다. 유행은 건강 관리 응용 분야에서 효율적인 화학 제제의 필요성을 부각시켰습니다. 유행 후, 제약 및 산업 자동화에 대한 지속적인 투자는 시장 성장을 유지할 것으로 예측됩니다.
예측 기간 동안 산업 등급 부문이 최대가 될 전망
산업 학년 부문은 광범위한 용도로 예측 기간 동안 최대 시장 점유율을 차지할 것으로 예측됩니다.
예측 기간 동안 솔벤트 부문의 CAGR이 가장 높을 것으로 예상
예측 기간 동안 솔벤트 분야가 가장 높은 성장률을 보일 것으로 예측됩니다. 고용도 용제에 대한 규제 당국의 지원은 시장의 성장을 더욱 뒷받침하고 있습니다.
예측 기간 동안 아시아태평양이 가장 큰 시장 점유율을 차지할 것으로 예측됩니다. 산업 자동화 및 화학 제조를 지원하는 정부 이니셔티브가 시장 성장을 더욱 촉진하고 있습니다. 아시아태평양에는 주요 시장 참여자가 있으며 생산 능력을 높이고 있습니다.
예측 기간 동안 북미가 가장 높은 CAGR을 보여줄 것으로 예측됩니다. 고순도 용제에 대한 투자가 가속화되고 있으며, 효율적인 공업 프로세스에 대한 수요 증가가 시장 확대를 뒷받침하고 있습니다.
According to Stratistics MRC, the Global Gamma Butyrolactone Market is accounted for $4.10 billion in 2025 and is expected to reach $5.88 billion by 2032 growing at a CAGR of 5.3% during the forecast period. Gamma Butyrolactone (GBL) is a colorless, hygroscopic liquid organic compound commonly used as a solvent and chemical intermediate. It has a faint odor and is soluble in water and most organic solvents. GBL plays a crucial role in the production of pharmaceuticals, polymers, and battery chemicals. It is also a precursor to other compounds like N-Methyl-2-pyrrolidone (NMP). Due to its potential misuse, GBL is regulated in many countries.
Growing demand in pharmaceuticals
GBL serves as a precursor in the synthesis of various drugs, including anesthetics and sedatives. The increasing demand for high-purity solvents in pharmaceutical manufacturing is driving market expansion. Additionally, the rising prevalence of chronic diseases has led to higher prescription volumes, further boosting demand. Regulatory support for advanced pharmaceutical formulations is encouraging the adoption of GBL-based solvents. As a result, the pharmaceutical sector remains a key driver of GBL market growth.
Fluctuating raw material prices
GBL production relies on precursor chemicals, whose costs fluctuate due to geopolitical tensions and supply chain disruptions. Manufacturers face difficulties in maintaining stable pricing, impacting profit margins. Sudden price hikes can lead to increased production costs, making it harder for companies to remain competitive. Despite these efforts, price instability remains a significant restraint for market growth.
Increased production of polymers and resins
GBL is widely used in the synthesis of polyurethanes, which are essential in automotive, construction, and furniture industries. The expansion of these sectors, particularly in emerging economies, is driving the need for high-performance polymers. Additionally, advancements in polymer technology are increasing the adoption of GBL-based formulations. The versatility of GBL in resin production enhances its market potential. As industries seek innovative materials, the demand for GBL is expected to rise.
Competition from alternative solvents
Regulatory restrictions on certain chemical solvents are prompting industries to explore greener alternatives. Some substitutes offer similar performance characteristics at a reduced cost, challenging GBL's market position. Additionally, advancements in solvent technology are leading to the development of more efficient alternatives. Companies investing in sustainable solvent solutions may shift away from GBL-based formulations. As a result, competition from alternative solvents remains a key threat to market expansion.
Covid-19 Impact
The COVID-19 pandemic had a mixed impact on the Gamma Butyrolactone market. While disruptions in supply chains affected production, the demand for pharmaceutical solvents surged. Lockdowns and restrictions led to increased reliance on automated manufacturing processes, benefiting GBL adoption. The pandemic highlighted the need for efficient chemical formulations in healthcare applications. Post-pandemic, continued investment in pharmaceutical and industrial automation is expected to sustain market growth.
The industrial grade segment is expected to be the largest during the forecast period
The industrial grade segment is expected to account for the largest market share during the forecast period, due to its extensive applications. Industrial-grade GBL is widely used in chemical synthesis, cleaning agents, and electronic manufacturing. The demand for high-purity solvents in industrial processes is driving market expansion. Additionally, the growth of the electronics and automotive sectors is boosting the need for industrial-grade GBL.
The solvent segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the solvent segment is predicted to witness the highest growth rate, due to The increasing demand for high-performance solvents in pharmaceuticals, electronics, and agrochemicals is fuelling market expansion. Additionally, advancements in solvent technology are enhancing GBL's efficiency and versatility. Regulatory support for high-purity solvents is further boosting market growth. As industries seek reliable solvent solutions, the GBL market is expected to experience rapid growth.
During the forecast period, the Asia Pacific region is expected to hold the largest market share due to the region's expanding pharmaceutical and chemical industries are driving demand for Gamma Butyrolactone. Government initiatives supporting industrial automation and chemical manufacturing are further boosting market growth. The presence of key market players in Asia Pacific enhances production capabilities. Additionally, the rising demand for high-performance solvents in electronics and automotive sectors is contributing to expansion.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to the region's advanced healthcare infrastructure and strong regulatory framework support GBL adoption. The presence of leading pharmaceutical and chemical manufacturers is accelerating investment in high-purity solvents. Additionally, rising demand for efficient industrial processes is driving market expansion. The growing focus on sustainable chemical formulations is further boosting GBL adoption.
Key players in the market
Some of the key players profiled in the Gamma Butyrolactone Market include BASF SE, Mitsubishi Chemical Group Corporation, Ashland, Dairen Chemical Corporation (DCC), Sipchem Company, Balaji Amines, LyondellBasell Industries, Hefei TNJ Chemical Industry Co., Ltd., Zhejiang Realsun Chemical Co., Ltd., Chang Chun Group, Boai NKY Pharmaceuticals Ltd., Biosynth, CDH Fine Chemicals, Dongao Chemical, and Tokyo Chemical Industry Co., Ltd. (TCI).
In May 2025, BASF Coatings expands business with biomass-balanced products, BASF Coatings is consistently pursuing its strategic roadmap for sustainable development and is further expanding its business with biomass-balanced products. Following successful launches in Europe and Asia, the first products for the automotive refinish coatings market will now also be introduced in North America this year.
In May 2025, Mitsubishi Tanabe Pharma Corporation announced that Radicava(R) (generic name: edaravone, Japanese product name: RADICUT(R) inj.30mg) for an intravenous treatment for amyotrophic lateral sclerosis (ALS) has been launched in Australia on May 1 by a local licensee, Teva Pharma Australia Pty Ltd.